This paper presents preclinical data on a bispecific antibody, SAR446159, designed to target alpha-synuclein aggregates and cross the blood-brain barrier for treating synucleinopathies.

npj Parkinson s Disease · Aug 22, 2025Peer-reviewedNeuroscience

Elovl1 inhibition reduced very long chain fatty acids in a mouse model of adrenoleukodystrophy

Jeremy Y. Huang, Brian Freed, Martin Hanus, Kelly Keefe, Ming Sum Ruby Chiang, Alexander Brezzani, Yongyi Luo, Yihang Li, Becky Lam, Stephanie Holley, Joseph Gans, Zuzana Dostalova, Buyun Tang, Clifford G. Phaneuf, Erin A. Teeple, , Can Kayatekin

The paper inhibits Elovl1 in a mouse model of ALD to reduce VLCFA accumulation, finding it corrects lipid pathways but also causes unexpected transcriptional changes.

iScience · Jul 31, 2025Peer-reviewedPharmacology & Toxicology

Activation of Sarm1 produces cADPR to increase intra-axonal calcium and promote axon degeneration in CIPN

Yihang Li, Maria F. Pazyra‐Murphy, Daina Zofija Avizonis, Mariana De Sa Tavares Russo, Sophia Tang, Chiung-Ya Chen, Yi‐Ping Hsueh, Johann S. Bergholz, Tao Jiang, Jean J. Zhao, Jian Zhu, Kwang Woo Ko, Jeffrey Milbrandt, Aaron DiAntonio, Rosalind A. Segal

This study shows that paclitaxel induces cADPR production via Sarm1, increasing intra-axonal calcium and causing axon degeneration, with cADPR antagonists preventing neuropathy without affecting chemotherapy efficacy.

The Journal of Cell Biology · Dec 8, 2021Peer-reviewedNeuroscience